[Acinetobacter calcoaceticus, a potential pathogen with an increasing role in pathology].

Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol

Published: March 1985

Download full-text PDF

Source

Publication Analysis

Top Keywords

[acinetobacter calcoaceticus
4
calcoaceticus potential
4
potential pathogen
4
pathogen increasing
4
increasing role
4
role pathology]
4
[acinetobacter
1
potential
1
pathogen
1
increasing
1

Similar Publications

Soil contamination with toxic heavy metals [such as aluminum (Al)] is becoming a serious global problem due to the rapid development of the social economy. Although plant growth-promoting rhizo-bacteria (PGPR) are the major protectants to alleviate metal toxicity, the study of these bacteria to ameliorate the toxic effects of Al is limited. Therefore, the present study was conducted to investigate the combined effects of different levels of (5 ppm and 10 ppm) of accession number of MT123456 on plant growth and biomass, photosynthetic pigments, gas exchange attributes, oxidative stress and response of antioxidant compounds (enzymatic and nonenzymatic), and their specific gene expression, sugars, nutritional status of the plant, organic acid exudation pattern and Al accumulation from the different parts of the plants, which was spiked with different levels of Al [0 µM (i.

View Article and Find Full Text PDF

Background: Rates of carbapenem-resistant Acinetobacter baumannii are rising in Thailand. Although high-dose (HD) sulbactam is recommended for treating carbapenem-resistant A. baumannii infections, data on plasma sulbactam concentrations in children are limited.

View Article and Find Full Text PDF

Sulbactam-durlobactam is approved for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of complex. Patients with serious infections may require support with continuous renal replacement therapy (CRRT), which presents challenges for optimal dosing of antibiotics. Sulbactam-durlobactam dosing regimens were derived for this population using an CRRT model and Monte Carlo simulation (MCS).

View Article and Find Full Text PDF

Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by .

Expert Rev Anti Infect Ther

December 2024

Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.

Introduction: Carbapenem-resistant (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent and activity against CRAB. The phase III randomized trial (ATTACK) demonstrated the safety and efficacy of sulbactam-durlobactam in combination with imipenem-cilastatin as background therapy in treating adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by CRAB.

View Article and Find Full Text PDF

Nosocomial outbreak due to a novel sequence type of carbapenem-resistant Acinetobacter seifertii.

Am J Infect Control

November 2024

Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Bioinformatic Core, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Departamento de Microbiologia, Imunologia e Parasitologia, Instituto de Ciências Básicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

Background: Acinetobacter seifertii, a member of A baumannii-calcoaceticus complex, can be considered a pathogen of concern due to the presence of resistance genes. The aim of the study was to describe an outbreak of carbapenem-resistant A seifertii among neonates admitted to the neonatal intensive care unit (NICU) at a tertiary care hospital.

Methods: All patients with carbapenem-resistant A seifertii diagnosed and admitted to the NICU from June 2023 to October 2023 were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!